Understanding TERT Promoter Mutations: A Common Path to Immortality

  • Robert J.A. Bell
    1Department of Neurological Surgery, University of California, San Francisco, California.
  • H. Tomas Rube
    2Department of Biological Sciences, Columbia University, New York, New York.
  • Ana Xavier-Magalhães
    1Department of Neurological Surgery, University of California, San Francisco, California.
  • Bruno M. Costa
    3Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
  • Andrew Mancini
    1Department of Neurological Surgery, University of California, San Francisco, California.
  • Jun S. Song
    5Departments of Bioengineering and Physics, University of Illinois, Urbana-Champaign, Illinois.
  • Joseph F. Costello
    1Department of Neurological Surgery, University of California, San Francisco, California.

説明

<jats:title>Abstract</jats:title> <jats:p>Telomerase (TERT) activation is a fundamental step in tumorigenesis. By maintaining telomere length, telomerase relieves a main barrier on cellular lifespan, enabling limitless proliferation driven by oncogenes. The recently discovered, highly recurrent mutations in the promoter of TERT are found in over 50 cancer types, and are the most common mutation in many cancers. Transcriptional activation of TERT, via promoter mutation or other mechanisms, is the rate-limiting step in production of active telomerase. Although TERT is expressed in stem cells, it is naturally silenced upon differentiation. Thus, the presence of TERT promoter mutations may shed light on whether a particular tumor arose from a stem cell or more differentiated cell type. It is becoming clear that TERT mutations occur early during cellular transformation, and activate the TERT promoter by recruiting transcription factors that do not normally regulate TERT gene expression. This review highlights the fundamental and widespread role of TERT promoter mutations in tumorigenesis, including recent progress on their mechanism of transcriptional activation. These somatic promoter mutations, along with germline variation in the TERT locus also appear to have significant value as biomarkers of patient outcome. Understanding the precise molecular mechanism of TERT activation by promoter mutation and germline variation may inspire novel cancer cell-specific targeted therapies for a large number of cancer patients. Mol Cancer Res; 14(4); 315–23. ©2016 AACR.</jats:p>

収録刊行物

  • Molecular Cancer Research

    Molecular Cancer Research 14 (4), 315-323, 2016-04-01

    American Association for Cancer Research (AACR)

被引用文献 (11)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ